Ascletis Pharma Inc.
ASCLFOTCHealthcare● Active
$1.35
+$0.03(+2.27%)
Market Cap$1.4B
P/E Ratio—
52W High$2.5
52W Low$0.9325
Ascletis Pharma Inc. (ASCLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ASCLF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 31, 2026EPS Actual
-$0.04
Est. -$0.04 · +0.0%
Revenue
$0.00B
Est. $0.00B · -97.5%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 31, 2026
After Market Close
▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
ASCLF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 24, 2026 | -$0.03 | — | — | — | $0.01B | — |
| — Q1 FY2026 | Mar 31, 2026 | -$0.04 | -$0.04 | +0.0% | $0.00B | $0.00B | -97.5% |
| ▲ Q2 FY2025 | Jun 30, 2025 | -$0.02 | -$0.01 | +29.8% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 26, 2025 | -$0.02 | -$0.02 | -15.3% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 26, 2025 | -$0.02 | -$0.02 | -13.3% | $0.00B | — | — |
| ▼ Q3 FY2024 | Aug 30, 2024 | -$0.02 | -$0.02 | -6.8% | — | — | — |
| ▼ Q2 FY2024 | May 23, 2024 | -$0.01 | -$0.02 | -71.4% | $0.00B | $0.00B | -64.9% |
| ▼ Q2 FY2024 | May 23, 2024 | -$0.01 | -$0.02 | -72.9% | $0.00B | $0.00B | -51.1% |
Q3 FY2026
Aug 24, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 31, 2026
EPS Actual
-$0.04
EPS Est.
-$0.04
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
Jun 30, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.02
EPS Surpr.
+29.8%
Revenue
$0.00B
Q1 FY2025
Mar 26, 2025Miss
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
-15.3%
Revenue
$0.00B
Q1 FY2025
Mar 26, 2025Miss
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
-13.3%
Revenue
$0.00B
Q3 FY2024
Aug 30, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
-6.8%
Revenue
—
Q2 FY2024
May 23, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-71.4%
Revenue
$0.00B
Q2 FY2024
May 23, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-72.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.46 | $1.46 | $1.46 | 1 |
| Q3 FY2028 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q2 FY2028 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q1 FY2028 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q4 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.6B | $1.6B | $1.6B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 31, 2026 | +0.0% | $1.81 | $1.81 | +0.00% |
| ▲ Q2 FY2025 | Jun 30, 2025 | +29.8% | $0.93 | $0.93 | +0.00% |
| ▼ Q1 FY2025 | Mar 26, 2025 | -15.3% | $1.20 | $1.20 | +0.00% |
| ▼ Q1 FY2025 | Mar 26, 2025 | -13.3% | $1.20 | $1.20 | +0.00% |
| ▼ Q3 FY2024 | Aug 30, 2024 | -6.8% | $0.15 | $0.15 | +0.00% |
| ▼ Q2 FY2024 | May 23, 2024 | -71.4% | $0.20 | $0.15 | -25.16% |
| ▼ Q2 FY2024 | May 23, 2024 | -72.9% | $0.20 | $0.15 | -25.16% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +23.9% | No price data | $0.24 | — |
Q1 FY2026+0.00%
Report Date
Mar 31, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.81
Price After
$1.81
Q2 FY2025+0.00%
Report Date
Jun 30, 2025
EPS Beat/Miss
+29.8%
Price Before
$0.93
Price After
$0.93
Q1 FY2025+0.00%
Report Date
Mar 26, 2025
EPS Beat/Miss
-15.3%
Price Before
$1.20
Price After
$1.20
Q1 FY2025+0.00%
Report Date
Mar 26, 2025
EPS Beat/Miss
-13.3%
Price Before
$1.20
Price After
$1.20
Q3 FY2024+0.00%
Report Date
Aug 30, 2024
EPS Beat/Miss
-6.8%
Price Before
$0.15
Price After
$0.15
Q2 FY2024-25.16%
Report Date
May 23, 2024
EPS Beat/Miss
-71.4%
Price Before
$0.20
Price After
$0.15
Q2 FY2024-25.16%
Report Date
May 23, 2024
EPS Beat/Miss
-72.9%
Price Before
$0.20
Price After
$0.15
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
+23.9%
Price Before
—
Price After
$0.24
Avg Beat Reaction+0.00%
Avg Miss Reaction-10.06%
Beat Rate3 / 8 quarters
Largest Move-25.16% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ASCLF ends December
Ascletis Pharma Inc. (ASCLF) most recently reported earnings on March 31, 2026 for Q1 FY2026, posting EPS of $-0.04 (in line with the analyst consensus of $-0.04). ASCLF has beaten EPS estimates for 2 consecutive quarters. The next ASCLF earnings date is expected around September 1, 2026.
Each quarter, investors track ASCLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ASCLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ASCLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ASCLF earnings · 4 questionsAscletis Pharma Inc.'s next earnings report is expected around September 1, 2026. ASCLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ASCLF historically reports after market close (AMC).
ASCLF earnings datewhen is ASCLF earningsASCLF next earnings datewhen does ASCLF report earningsASCLF earnings calendar
▸ Source: FMP · Ascletis Pharma Inc. SEC filings · US GAAP · Ascletis Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026